A provider briefing on Clenpiq availability in 2026. Shortage status, prescribing implications, alternatives, cost data, and tools to help your patients.
Bowel preparation compliance is one of the most important — and most overlooked — factors in colonoscopy quality. When patients can't fill their Clenpiq prescription, it creates downstream problems: rescheduled procedures, incomplete preps, and frustrated patients who may delay screening altogether.
This briefing covers the current state of Clenpiq availability, what's driving the access issues, and practical steps you can take to keep your patients on track.
As of early 2026, Clenpiq is not listed on the FDA Drug Shortage Database. There is no formal nationwide shortage. However, providers across the country continue to report that patients are having difficulty filling Clenpiq prescriptions at retail pharmacies.
This is a distribution and stocking issue rather than a manufacturing shortage. The drug is being produced, but because it's a single-source brand product that many pharmacies don't routinely stock, patients frequently encounter "out of stock" responses — especially at chain pharmacies that rely on automated ordering systems.
Key dates and context for Clenpiq:
The Clenpiq availability situation creates several practical considerations for prescribers:
When a patient picks up their colonoscopy prep and the pharmacy doesn't have it, the default outcome is often a delayed colonoscopy. Studies consistently show that delays in colorectal cancer screening reduce detection rates and worsen outcomes. Anything that creates friction in the prep process is a barrier to screening compliance.
Consider writing the Clenpiq prescription well in advance of the scheduled procedure — ideally 1–2 weeks ahead. This gives the pharmacy time to order it and gives the patient time to find an alternative pharmacy if needed.
Having a backup plan in place before the patient encounters a stock-out saves time and prevents last-minute scrambling. Many practices now include a note in their colonoscopy scheduling workflow: "If Clenpiq is unavailable, contact our office for an alternative prescription."
Understanding the distribution dynamics helps explain why patients struggle:
Cost can be a secondary barrier, particularly for uninsured or underinsured patients:
For a patient-facing cost guide to share: How to Save Money on Clenpiq in 2026.
Medfinder for Providers allows you to check real-time pharmacy stock for Clenpiq and other medications in your patient's area. This can be integrated into your colonoscopy scheduling workflow to proactively identify availability issues before they become patient problems.
When Clenpiq isn't available, consider these evidence-based alternatives:
Each has different contraindication profiles, particularly regarding renal function. Clenpiq and Suprep both contain magnesium and require caution in patients with CrCl <30 mL/min. GoLYTELY may be preferred in patients with significant renal impairment.
These patient-facing articles can be shared with patients who are having trouble finding Clenpiq:
With Clenpiq patents extending through 2034, generic competition is unlikely in the near term. The practical reality for prescribers is that Clenpiq will remain a single-source product with periodic access challenges for the foreseeable future.
To mitigate this:
The Clenpiq availability situation in 2026 is manageable but requires proactive planning. As the sole prescriber in the colonoscopy prep equation, you have significant influence over whether a stock-out becomes a delayed screening or a seamless switch to an alternative. Building availability checks and backup plans into your workflow protects your patients and your procedure schedule.
Additional resources for your practice:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
